222 related articles for article (PubMed ID: 24093937)
1. Are ABCB1 (P-glycoprotein) polymorphisms clinically relevant in ovarian cancer? - Finally an Answer!
Konecny GE
Gynecol Oncol; 2013 Oct; 131(1):1-2. PubMed ID: 24093937
[No Abstract] [Full Text] [Related]
2. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C; Fereday S; Webb PM; ; Goode EL; Vierkant RA; Fridley BL; Cunningham JM; Fasching PA; Beckmann MW; Ekici AB; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Brown R; Paul J; Lambrechts S; Despierre E; Vergote I; Lester J; Karlan BY; Heitz F; du Bois A; Harter P; Schwaab I; Bean Y; Pejovic T; Levine DA; Goodman MT; Camey ME; Thompson PJ; Lurie G; Shildkraut J; Berchuck A; Terry KL; Cramer DW; Norris MD; Haber M; MacGregor S; deFazio A; Chenevix-Trench G
Gynecol Oncol; 2013 Oct; 131(1):8-14. PubMed ID: 23917080
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Chen Y; Bieber MM; Teng NN
Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
[TBL] [Abstract][Full Text] [Related]
4. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
5. [Proteins of resistance and drug resistance in ovarian carcinoma patients].
Sedláková I; Laco J; Tošner J; Caltová K; Cervinka M; Rezáč A; Spaček J; Skapinec P
Klin Onkol; 2012; 25(6):457-63. PubMed ID: 23301649
[TBL] [Abstract][Full Text] [Related]
6. Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma.
Koh I; Hinoi T; Sentani K; Hirata E; Nosaka S; Niitsu H; Miguchi M; Adachi T; Yasui W; Ohdan H; Kudo Y
Cancer Med; 2016 Jul; 5(7):1546-55. PubMed ID: 27060927
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance in epithelial ovarian cancer: P-glycoprotein and glutation S-transferase. Can they play an important role in detecting response to platinum-based chemotherapy as a first-line therapy.
Simşek T; Ozbilim G; Gülkesen H; Kaya H; Sargin F; Karaveli S
Eur J Gynaecol Oncol; 2001; 22(6):436-8. PubMed ID: 11878288
[TBL] [Abstract][Full Text] [Related]
8. Human epididymis protein 4 promotes P‑glycoprotein‑mediated chemoresistance in ovarian cancer cells through interactions with Annexin II.
Liu Q; Liu DW; Zheng MJ; Deng L; Wang HM; Jin S; Liu JJ; Hao YY; Zhu LC; Lin B
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33955501
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
Duan Z; Brakora KA; Seiden MV
Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance: genes, polymorphisms, biologic effects, reversal and treatment in cancer chemotherapy.
Aragon-Ching JB
Anticancer Agents Med Chem; 2010 Oct; 10(8):582. PubMed ID: 21244347
[No Abstract] [Full Text] [Related]
11. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
12. The
Yin B; Lu P; Liang J; Zhang W; Xin M; Pei K; Li Y
J Int Med Res; 2019 Oct; 47(10):5256-5269. PubMed ID: 31638462
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
14. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
Gao Y; Foster R; Yang X; Feng Y; Shen JK; Mankin HJ; Hornicek FJ; Amiji MM; Duan Z
Oncotarget; 2015 Apr; 6(11):9313-26. PubMed ID: 25823654
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer.
Sedláková I; Laco J; Caltová K; Červinka M; Tošner J; Řezáč A; Špaček J
Int J Gynecol Cancer; 2015 Feb; 25(2):236-43. PubMed ID: 25594141
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Pontikakis S; Papadaki C; Tzardi M; Trypaki M; Sfakianaki M; Koinis F; Lagoudaki E; Giannikaki L; Kalykaki A; Kontopodis E; Saridaki Z; Malamos N; Georgoulias V; Souglakos J
Pharmacogenomics J; 2017 Dec; 17(6):506-514. PubMed ID: 27779244
[TBL] [Abstract][Full Text] [Related]
19. Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.
Wang SQ; Liu ST; Zhao BX; Yang FH; Wang YT; Liang QY; Sun YB; Liu Y; Song ZH; Cai Y; Li GF
Oncotarget; 2015 Sep; 6(28):26142-60. PubMed ID: 26317651
[TBL] [Abstract][Full Text] [Related]
20. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X
Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]